• Je něco špatně v tomto záznamu ?

Population Pharmacokinetic Analysis Proves Superiority of Continuous Infusion in PK/PD Target Attainment with Oxacillin in Staphylococcal Infections

I. Murínová, M. Švidrnoch, T. Gucký, J. Hlaváč, P. Michálek, O. Slanař, M. Šíma

. 2022 ; 11 (12) : . [pub] 20221201

Status neindexováno Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22031143

Considering its very short elimination half-life, the approved oxacillin dosage might not be sufficient to maintain the pharmacokinetic/pharmacodynamics (PK/PD) target of time-dependent antibiotics. This study aimed to describe the population pharmacokinetics of oxacillin and to explore the probability of PK/PD target attainment by using various dosing regimens with oxacillin in staphylococcal infections. Both total and unbound oxacillin plasma concentrations retrieved as a part of routine therapeutic drug-monitoring practice were analyzed using nonlinear mixed-effects modeling. Monte Carlo simulations were used to generate the theoretical distribution of unbound oxacillin plasma concentration-time profiles at various dosage regimens. Data from 24 patients treated with oxacillin for staphylococcal infection have been included into the analysis. The volume of distribution of oxacillin in the population was 11.2 L, while the elimination rate constant baseline of 0.73 h-1 increased by 0.3 h-1 with each 1 mL/s/1.73 m2 of the estimated glomerular filtration rate (eGFR). The median value of oxacillin binding to plasma proteins was 86%. The superiority of continuous infusion in achieving target PK/PD values was demonstrated and dosing according to eGFR was proposed. Daily oxacillin doses of 9.5 g, 11 g, or 12.5 g administered by continuous infusion have been shown to be optimal for achieving target PK/PD values in patients with moderate, mild, or normal renal function, respectively.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22031143
003      
CZ-PrNML
005      
20230127131045.0
007      
ta
008      
230119s2022 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/antibiotics11121736 $2 doi
035    __
$a (PubMed)36551393
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Murínová, Irena $u Department of Clinical Pharmacy, Military University Hospital Prague, 16902 Prague, Czech Republic $u Department of Applied Pharmacy, Faculty of Pharmacy, Masaryk University, 60177 Brno, Czech Republic
245    10
$a Population Pharmacokinetic Analysis Proves Superiority of Continuous Infusion in PK/PD Target Attainment with Oxacillin in Staphylococcal Infections / $c I. Murínová, M. Švidrnoch, T. Gucký, J. Hlaváč, P. Michálek, O. Slanař, M. Šíma
520    9_
$a Considering its very short elimination half-life, the approved oxacillin dosage might not be sufficient to maintain the pharmacokinetic/pharmacodynamics (PK/PD) target of time-dependent antibiotics. This study aimed to describe the population pharmacokinetics of oxacillin and to explore the probability of PK/PD target attainment by using various dosing regimens with oxacillin in staphylococcal infections. Both total and unbound oxacillin plasma concentrations retrieved as a part of routine therapeutic drug-monitoring practice were analyzed using nonlinear mixed-effects modeling. Monte Carlo simulations were used to generate the theoretical distribution of unbound oxacillin plasma concentration-time profiles at various dosage regimens. Data from 24 patients treated with oxacillin for staphylococcal infection have been included into the analysis. The volume of distribution of oxacillin in the population was 11.2 L, while the elimination rate constant baseline of 0.73 h-1 increased by 0.3 h-1 with each 1 mL/s/1.73 m2 of the estimated glomerular filtration rate (eGFR). The median value of oxacillin binding to plasma proteins was 86%. The superiority of continuous infusion in achieving target PK/PD values was demonstrated and dosing according to eGFR was proposed. Daily oxacillin doses of 9.5 g, 11 g, or 12.5 g administered by continuous infusion have been shown to be optimal for achieving target PK/PD values in patients with moderate, mild, or normal renal function, respectively.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Švidrnoch, Martin $u Laboratory of Pharmacology and Toxicology, AGEL Laboratories, 74101 Novy Jicin, Czech Republic
700    1_
$a Gucký, Tomáš $u Laboratory of Pharmacology and Toxicology, AGEL Laboratories, 74101 Novy Jicin, Czech Republic
700    1_
$a Hlaváč, Jan $u Department of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, 12800 Prague, Czech Republic
700    1_
$a Michálek, Pavel $u Department of Anaesthesia and Intensive Care, First Faculty of Medicine, Charles University and General University Hospital in Prague, 12808 Prague, Czech Republic $1 https://orcid.org/0000000181195927
700    1_
$a Slanař, Ondřej $u Department of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, 12800 Prague, Czech Republic $1 https://orcid.org/0000000253577562
700    1_
$a Šíma, Martin $u Department of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, 12800 Prague, Czech Republic $1 https://orcid.org/000000026541738X
773    0_
$w MED00195446 $t Antibiotics (Basel, Switzerland) $x 2079-6382 $g Roč. 11, č. 12 (2022)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36551393 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230119 $b ABA008
991    __
$a 20230127131037 $b ABA008
999    __
$a ok $b bmc $g 1889385 $s 1182476
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2022 $b 11 $c 12 $e 20221201 $i 2079-6382 $m Antibiotics (Basel) $n Antibiotics $x MED00195446
LZP    __
$a Pubmed-20230119

Najít záznam

Citační ukazatele

Možnosti archivace